GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Beneish M-Score

AngioLab (XKRX:251280) Beneish M-Score : 0.60 (As of Apr. 17, 2025)


View and export this data going back to 2016. Start your Free Trial

What is AngioLab Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.6 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for AngioLab's Beneish M-Score or its related term are showing as below:

XKRX:251280' s Beneish M-Score Range Over the Past 10 Years
Min: -6.19   Med: -1.14   Max: 3.74
Current: 0.6

During the past 8 years, the highest Beneish M-Score of AngioLab was 3.74. The lowest was -6.19. And the median was -1.14.


AngioLab Beneish M-Score Historical Data

The historical data trend for AngioLab's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Beneish M-Score Chart

AngioLab Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial 3.74 -4.26 -2.87 1.84 0.60

AngioLab Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score Get a 7-Day Free Trial 3.74 -4.26 -2.87 1.84 0.60

Competitive Comparison of AngioLab's Beneish M-Score

For the Biotechnology subindustry, AngioLab's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioLab's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AngioLab's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AngioLab's Beneish M-Score falls into.


;
;

AngioLab Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AngioLab for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1005+0.528 * 0.2896+0.404 * 1.3566+0.892 * 4.1165+0.115 * 0.8998
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.176+4.679 * 0.258406-0.327 * 0.9338
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was ₩64 Mil.
Revenue was ₩2,044 Mil.
Gross Profit was ₩1,434 Mil.
Total Current Assets was ₩1,728 Mil.
Total Assets was ₩2,280 Mil.
Property, Plant and Equipment(Net PPE) was ₩127 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩100 Mil.
Selling, General, & Admin. Expense(SGA) was ₩211 Mil.
Total Current Liabilities was ₩999 Mil.
Long-Term Debt & Capital Lease Obligation was ₩26 Mil.
Net Income was ₩-794 Mil.
Gross Profit was ₩0 Mil.
Cash Flow from Operations was ₩-1,383 Mil.
Total Receivables was ₩156 Mil.
Revenue was ₩497 Mil.
Gross Profit was ₩101 Mil.
Total Current Assets was ₩3,206 Mil.
Total Assets was ₩3,919 Mil.
Property, Plant and Equipment(Net PPE) was ₩175 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩114 Mil.
Selling, General, & Admin. Expense(SGA) was ₩291 Mil.
Total Current Liabilities was ₩1,842 Mil.
Long-Term Debt & Capital Lease Obligation was ₩44 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(64.497 / 2044.464) / (155.963 / 496.646)
=0.031547 / 0.314033
=0.1005

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(100.926 / 496.646) / (1434.473 / 2044.464)
=0.203215 / 0.701638
=0.2896

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1728.32 + 126.894) / 2279.662) / (1 - (3205.956 + 174.77) / 3918.531)
=0.186189 / 0.137247
=1.3566

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2044.464 / 496.646
=4.1165

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(114.488 / (114.488 + 174.77)) / (99.652 / (99.652 + 126.894))
=0.395799 / 0.439875
=0.8998

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(210.518 / 2044.464) / (290.589 / 496.646)
=0.10297 / 0.585103
=0.176

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((26.165 + 998.543) / 2279.662) / ((43.969 + 1842.377) / 3918.531)
=0.4495 / 0.481391
=0.9338

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-793.963 - 0 - -1383.041) / 2279.662
=0.258406

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AngioLab has a M-score of 0.60 signals that the company is likely to be a manipulator.


AngioLab Beneish M-Score Related Terms

Thank you for viewing the detailed overview of AngioLab's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioLab Business Description

Traded in Other Exchanges
N/A
Address
65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab Headlines

No Headlines